ArticleEmerging infectious diseases2016
Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Research prioritisation in preparedness for and response to outbreaks of high-consequence pathogens: a scoping review.BMC medicine · 2025Article
- Drug Repurposing: Insights into Current Advances and Future Applications.Current medicinal chemistry · 2025Review
- (+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay.Scientific reports · 2022Article
- Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.Life sciences · 2020Review
- Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.Nanomaterials (Basel, Switzerland) · 2020Review
- Core Minimal Datasets to Advance Clinical Research for Priority Epidemic Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Systems Biology Approaches for Therapeutics Development Against COVID-19.Frontiers in cellular and infection microbiology · 2020Review
- A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals.Biosafety and health · 2019Article
- Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.ACS applied materials & interfaces · 2019Article
- Article
- Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.Human vaccines & immunotherapeutics · 2019Review
- An updated roadmap for MERS-CoV research and product development: focus on diagnostics.BMJ global health · 2019Article
- Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Review
- Article
- Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).Expert review of anti-infective therapy · 2017Review
- The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic.Journal of microbiology (Seoul, Korea) · 2017Review
- An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus.Annals of translational medicine · 2016Article
- Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.